Vas Narasimhan

CEO, Novartis · 1 appearance on the record.

computed by AI from the episodes · how this works → · full disclaimer →

executivescientistLinkedIn ↗novartis.com ↗Wikipedia ↗

A Harvard-trained physician-scientist, he has led Novartis as CEO since 2018, pivoting the multinational into a pure-play innovative medicines company through strategic deals and the 2023 spinoff of Sandoz. He previously served as Novartis’s Global Head of Drug Development and Chief Medical Officer.

26statements → 13claims → 6claims resolved → 67%fully supported → 4/5average certainty → 1.96/5average debate potential → 4.4/5argument clarity · the sources → 4said about them ↓

4 supported 1 partly supported 1 contradicted 1 not yet assessed 6 not checkable as stated how the 13 claims stand · each chip opens the sources

3 predictions · 10 assertions · 3 opinions · 3 insights · 7 disclosures · every statement was checked. The predictions and assertions are the 13 claims: statements the public record can support or contradict. 6 are resolved, 1 is not yet assessed, and 6 name no date, number or outcome precise enough to check. Everything else (opinions, insights, what ifs, disclosures) can never be settled by the record, so it carries no assessment.

The record, in short

What the tape says about how Vas argues and how the claims held up. Everything they said, and everything said about them, is in the tabs below.

Their most notable supported claim

Assertion Supported
Novartis launched first FDA-approved prescription app for opioid addiction
“I mean, one example we launched in the U S a digital medicine. I mean, with paratherapeutics, this is the first digital app with an FDA label that's being used for opioid addiction and other psychiatric illnesses. And it is literally an app That has run clinic…”
Vas Narasimhan Jan 17, 2019 ▶ 13:54 a16z Podcast | The Science and Business of Innovative Medicines

Their most notable contradicted claim

Assertion Contradicted
Narasimhan: RNA therapies are the only way to drug LP(a)
“And so the only way to really target it turns out to be using RNA based therapies. These RNA based therapies are able to block the production of the gene translation of the gene into the protein and then actually reduce the LP little a in the blood.”
Vas Narasimhan Jan 17, 2019 ▶ 25:55 a16z Podcast | The Science and Business of Innovative Medicines

Expressed certainty vs assessment result

none yet certainty 1
none yet certainty 2
100% certainty 3
0% certainty 4
83% certainty 5

weighted support: a fully supported claim counts one, a partly supported claim counts half. Each filled bar is clickable and opens exactly those claims; "none yet" means nothing said at that certainty level has resolved yet

Argument clarity: do they answer the question? how? →

4.4 / 5 directness 4.4 · coherence 4.8 · precision 4.4 · compression 3.9

redirected or did not address 1 of 17 assessed questions (6%). Watch them ▸

This is a score against a rubric. It is not a rank. Every host question → answer exchange is scored with names hidden on directness, coherence, precision and compression, 1–5 each, on meaning alone: disfluencies are ignored, and only raw unedited episodes count. This is the score that measures thought. Every scored exchange, scores shown → · The rubric and its checks →

How they sound: speaking style how? →

249 words/min while actually speaking · 13.8 um and uh per 1k words · 30 false starts per 1k · 30.2% of pauses land inside a clause

Measured by listening to the audio itself: 8,163 words across 1 episode of raw-level tape, transcribed verbatim with every um and uh kept, each one attributed only where the alignment onto our timed stream is unambiguous. These are measurements of speaking style. We do not rank them: across this corpus, fluency and argument quality are nearly uncorrelated (ρ≈0.2), and smooth talking does not signal clear thinking. How it's measured →

Everything Vas Narasimhan said on the a16z Podcast that made the record, most notable first. Filter by type, assessment or year in the ledger →

Assertion Supported
The FDA has approved only about 1,500 new molecular entities in history
“Since the creation of the FDA, there's only been about 1500 new molecular entities ever found.”
Vas Narasimhan Jan 17, 2019 ▶ 58:00 a16z Podcast | The Science and Business of Innovative Medicines
Assertion Supported
Narasimhan: 80% of Novartis's drug volume is generics
“I would say roughly 80%.”
Vas Narasimhan Jan 17, 2019 ▶ 12:48 a16z Podcast | The Science and Business of Innovative Medicines

The other half of the tape: Vas Narasimhan's own voice is left out of every number here. Other people bring the name up 4 times in 1 episode on the a16z Podcast. every mention, with the transcript →

Who brings them up most Koki Hirasaki 4

Every mention by year

tap a year for its mentions
0021412019episodesmentions
0112019episodes it came up in
0020.5412019episodesmentions per episode
2019 4 mentions in 1 episode

Appearances (1)

EpisodeDateSpeaking time
a16z Podcast | The Science and Business of Innovative Medicines Jan 17, 2019 37m
Made with StarZero

Turn any episode into a week of clips.

This entire site, over 1,000 episodes transcribed, diarized, checked and made playable, runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the moments worth sharing, cuts them, captions them, and reframes them for every feed.